Loading stock data…
$0.22-0.01 (-5.29%)
Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc. in the Healthcare sector is trading at $0.22 with a market capitalization of $4M. Wall Street consensus targets $56.00 (1 analysts), implying a +24922.3% move over the next 12 months. The stock is currently near its 52-week low of $0.21, remaining 96.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $9.26M↑ | $8.09M↓ | $8.58M↓ | $9.42M | $9.41M |
| Gross Profit | $2.43M↑ | $2.18M↓ | $3.03M↓ | $3.07M↓ | $3.42M |
| Operating Income | -$1.61M↓ | -$1.40M↑ | -$1.66M↓ | -$531,963↑ | -$992,846 |
| Net Income | -$1.56M↓ | -$1.24M↑ | -$2.14M↓ | -$883,820↑ | -$1.77M |
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is develo...